Novel strategies to control the binding of adhesion molecules belonging to the selectin family are required for the treatment of inflammatory diseases. We tested the possibility that synthetic monosaccharide analogs can compete with naturally occurring sugars to alter the O-glycan content on human leukocyte cell surface selectin-ligand, P-selectin glycoprotein ligand-1 (PSGL-1). Resulting reduction in the sialyl Lewis-X (sLe X ) bearing epitopes on this ligand may then reduce cell adhesion.
INTRODUCTION
The binding of adhesion molecules belonging to the selectin family to carbohydrate ligands facilitate the adhesion of blood leukocytes to activated endothelial cells, platelets and other leukocytes in the human vasculature 1, 2 . Such molecular interactions play an important role in regulating leukocyte recruitment at sites of inflammation, cancer metastasis and various cardiovascular disorders 3 . While numerous glycoproteins and glycolipids participate in selectin mediated cell adhesion, interactions with carbohydrate epitopes expressed on the leukocyte glycoprotein P-selectin glycoprotein ligand-1 (PSGL-1, CD162) are particularly important since this ligand binds all three members of the selectin family (E-, Pand L-selectin) with high affinity and under fluid flow conditions. Structural analysis of the glycans of PSGL-1 expressed on human promyelocytic leukemia HL-60 cells reveal that PSGL-1 is predominantly composed of core-2 based O-linked glycans 4, 5 . The prototypic selectin-binding carbohydrate structure sialyl Lewis-X (NeuAcα2,3Galβ1,4(Fucα1,3)GlcNAc-, sLe X , Fig. 1a ) is expressed on 2-14% of these Oglycans.
There is active interest in developing antagonists that control/block selectin mediated cell adhesion using either competitive inhibitors or metabolic inhibitors. Competitive inhibitors attempt to block cell adhesion by regulating the ligand-binding epitope of either the selectin or its primary counterreceptor PSGL-1. Antagonists used for such inhibition include the tetrasaccharide sialyl Lewis-X and its glycomimetics 6 , humanized antibodies directed against selectins [7] [8] [9] , and soluble recombinant PSGL-1-Ig fusion protein 10 . Only limited clinical success has been reported with these molecules, thus far 11 . While the use of competitive inhibitors is conceptually straightforward, in practice this is complicated by the overlapping functional redundancies among the members of the selectin family and their carbohydrate ligands, the multiple roles of selectins in both ligand binding and signaling, and the limited half-life in circulation of some classes of inhibitors.
The use of metabolic inhibitors is more recent and less well-developed. These are mostly designed based on the growing knowledge of cellular glycosylation reactions and pathways. This approach employs small molecules that penetrate the cell to divert/block metabolic pathways that
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 4 normally lead to the formation of selectin-binding carbohydrate epitopes. This strategy targets a group of related cellular reactions as opposed to a single pathway. Preliminary success has been noted using this approach. First, surrogate-acceptors or decoys that act as unnatural substrates for glycosyltransferases have been introduced into cells. Glycosyltransferases act on such artificial substrates. This results in incomplete glycosylation of the natural glycoconjugates. While an early approach showed that aryl-Nacetyl-α-galactosaminides (Benzl, Phenyl, p-nitrophenyl-α-GalNAc) added to cell culture media can alter glycans on mucinous glycoproteins, these reagents were applied at high concentrations (1-7.5mM) 12 .
Later, it was demonstrated that per-acetylated forms of Galβ1,4GlcNAc-β-O-napthalenemethanol (NAP) and GlcNAcβ1,3Gal-β-O-NAP at 50μM can act as decoys/primers that block selectin-ligand formation [13] [14] [15] [16] . Second, glycosyltransferase inhibitors are also in development based on the structure of the sugarnucleotide transition-state analogs 17, 18 and high throughput screens 19 , though testing of these reagents has largely been performed in cell-free enzymatic assays. Third, per-acetylated, modified monosaccharides have been applied to cells as these may compete with the natural monosaccharides. Here, unnatural monosaccharides are incorporated into cellular glycoconjugates [20] [21] [22] [23] [24] . While analogs of Galactose, GlcNAc, GalNAc and Mannose have been synthesized, only limited studies have been conducted in cellular assays [25] [26] [27] . 4F-GlcNAc is an example of this class of inhibitors. This molecule reduces selectin mediated CLA + (cutaneous lymphocyte-associated antigen) T-cell adhesion in vitro 28 , and in in vivo models of skin inflammation [29] [30] [31] .
Since O-linked glycans linked to PSGL-1 and other glycoproteins participate as important selectin-ligands and since the attachment of GalNAc to serine/threonine residues on the peptide backbone is critical for the initiation of O-glycan assembly, we tested the hypothesis that modified monosaccharides based on GalNAc may be used to disrupt/alter the pattern of O-linked glycosylation. This can result in reduced selectin binding function. In this regard, unlike GlcNAc which plays a major role in modifying 
MATERIALS AND METHODS

Supplemental Methods
Supplemental Material contains details on many procedures used in this work. Chemical synthesis of acetylated monosaccharides, fluorinated analogs and radioactive [
14 C]4F-GalNAc (Fig. 1b) is described here. 
Cell culture
Cytometry-bead assay and western blotting
The carbohydrate structure(s) on PSGL-1 was assessed by immunoprecipitating this protein from HL-60 lysates. Quantitative cytometry-bead assays and qualitative western blot analysis was performed (Supplemental Material and reference 35 ).
Briefly, in each cytometry-bead experiment, PSGL-1 from 200-400µg cell lysate was immunoprecipitated onto "TB5-beads" (6µm polystyrene beads with covalently immobilized anti-PSGL-1 mAb TB5). The binding of fluorescent reagents to these beads was measured. These includes FITC conjugated HECA-452, FITC-DSA lectin, and unconjugated anti-PSGL-1 antibody (H-300, rabbit pAb)
followed by FITC-conjugated F(ab') 2 mouse-anti-rabbit IgG. Mean fluorescence intensity from control experiments performed in the absence of cell lysate was subtracted from all data presented in figures.
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For western blots, PSGL-1 immunoprecipitated using 7µg/ml anti-PSGL-1 (H-300) and protein A/G beads was separated using either 8% or 4-20% gradient Tris-SDS-PAGE gel. In experiments with radiolabeled compounds, protein blotted onto nitrocellulose membrane was visualized using phosphorimaging. In other studies, the membrane was probed with anti-PSGL-1 mAb (KPL-1) or HECA-452 followed by appropriate HRP-conjugated secondary Abs, and chemiluminescence detection. 
Mouse peritonitis model
RESULTS
We evaluated the ability of synthetic monosaccharide analogs, primarily 4F-GalNAc and also 4F-GlcNAc (Fig. 1b) , to alter carbohydrate structures on PSGL-1 and the selectin binding function of leukocytes. All carbohydrates were acetylated to enhance their cell-permeability. Acetyl groups are hydrolysed by intracellular esterases 13 .
4F-GalNAc reduces leukocyte P-selectin binding and the expression of cell-surface CLA and sLe
X epitopes
Two types of experiments were performed. Similar to a recent publication 28 , in some cases, HL-60 were treated with neuraminidase to remove cell-surface sialic acid prior to addition of acetylated monosaccharide ( Fig. 2a-h ). Neuraminidase reduced P-selectin binding to HL-60 by 85% (Fig. 2a , data at t=0h) and cell-surface CLA/HECA expression by 90% (Fig. 2b) . The anti-CLA mAb HECA-452 binds both CD15s/sLe X and other sLe X -like antigens 37 (Fig. 1a) . No change in PSGL-1 levels was noted ( Fig.   2c ), though Le X expression (data not shown) and DSA-lectin binding (Fig. 2d) increased by 900% and 20% respectively. Since DSA-lectin recognizes Galβ1,4GlcNAc structures (Fig. 1a) , the data suggest that removal of sialic acid exposes new terminal LacNAc structures. In other runs, monosaccharides were added without prior sialidase treatment ( Fig. 2i-l) . While the first set of experiments examine CLA and sLe X expression, and P-selectin binding function of newly synthesized PSGL-1 only, the latter also account for the recycling of PSGL-1 and the effects of cell division.
Following neuraminidase removal at t=0h, cells were allowed to grow in normal culture media containing either acetylated monosaccharides at indicated dose ( Fig. 2e-h ) or vehicle control ( Fig. 2a-d ).
In vehicle control, P-selectin fusion protein binding returned to baseline levels by 14h (Fig. 2a) , while CLA/HECA took 36h (Fig. 2b) . Addition of 4F-GalNAc reduced P-selectin binding in a dose-dependent manner ( 
4F-GalNAc reduces L-and E-selectin fusion protein binding to HL-60
We tested if E-and L-selectin IgG binding to monosaccharide treated cells is also reduced (Fig.   3a) . Control runs verified the specificity of the measured interaction by demonstrating that selectin binding was blocked by either 5mM EDTA, 2mM sLe X analog TBC1269, or blocking antibodies against individual selectins. Addition of 50µM 4F-GalNAc to growth medium resulted in 80% and 60% reduction in E-and L-selectin binding respectively to HL-60 cells at 38h, compared to vehicle control. Thus, 4F-GalNAc functions as a pan-selectin inhibitor.
Reduction in CLA and sLe X expression upon 4F-GalNAc treatment could be due to alteration in the extent of fucosylation in addition to the extent of sialylation. To test this possibility, cytometry studies 11 were performed with antibodies and AAL, an α 1,3/4/6-fucose binding lectin (Fig. 1a) . As seen, Le X epitope expression and AAL binding decreased by 73% and 40% respectively in 4F-GalNAc supplemented cells compared to vehicle control (Fig. 3b) . AAL lectin binding specificity for fucose was verified using 100mM L-Fucose, which abrogated lectin binding interaction. Thus, reduction in the extent of fucosylation may partly account for the reduced selectin binding.
Treatment with 4F-GalNAc increases leukocyte rolling velocity
The ability of 4F-GalNAc to reduce selectin mediated cell adhesion under fluid flow was measured using parallel-plate flow chambers (Fig. 4) . HL-60 were pretreated with neuraminidase prior to culture with either vehicle control or 4F-GalNAc for 38h. Thereafter, the binding of these cells to Eselectin bearing cell monolayers ( HL-60 were cultured with 4F-GalNAc. The firmly attached cells were likely due to the high density of Eselectin on the L-E/I monolayer since most of these cells could be detached upon increasing the shear stress to 6 dyn/cm 2 . This interaction could also be blocked by anti-E-selectin mAb.
In control runs, cell rolling via both E-and P-selectin was absent upon chelating calcium with 5mM EDTA. HL-60 also did not interact with substrates bearing rabbit-anti-mouse F(ab') 2 antibody alone in the absence of P-selectin-IgG. Further, HL-60 rolling/adhesive interactions to either P-selectin or EFor personal use only. on September 24, 2017. by guest www.bloodjournal.org From selectin bearing substrates could be completely blocked upon incubation of substrates with anti-P-selectin mAb G1 or anti-E-selectin mAb EP5C7. Experiments performed with control per-acetylated GalNAc resulted in cell rolling phenotype that was similar to vehicle control. Overall, 4F-GalNAc substantially increased E-and P-selectin mediated cell rolling velocities. This may be due to alterations in the carbohydrate structure of PSGL-1.
4F-GalNAc reduces the molecular weight of leukocyte PSGL-1 and the expression of CLA/HECA and LacNAc epitopes on this glycoprotein
We determined the effect of 4F-GalNAc on PSGL-1 glycosylation (Fig. 5) . With the goal of obtaining quantitative results and time-course data rapidly, polystyrene beads covalently linked with anti-PSGL-1 mAb TB5 ("TB5-beads") and cytometry based assays were developed (Supplemental Fig. S3 ). In these assays, PSGL-1 from cell lysate was first captured onto TB5-beads via immuno-affinity. Following this, the beads were probed with either: i) FITC-conjugated anti-CLA mAb HECA-452, ii) FITC-labeled DSA-lectin to detect LacNAc structures, or iii) anti-PSGL-1 antibody H-300 (rabbit IgG) along with FITC-labeled mouse-anti-rabbit secondary Ab. Competitive binding assays, blocking studies and isotypecontrol beads described in Fig. S3 , confirm that this assay specifically probes changes in glycan structures associated with PSGL-1.
Our experiments monitored PSGL-1 in cells cultured in the presence of 50µM GalNAc, 4F-GalNAc or 4F-GlcNAc. (Fig. 5a,b) . After 36h, CLA/HECA expression and DSA lectin binding was reduced by 86% and 73% respectively upon 50μM 4F-GalNAc treatment, compared to 10% and 53% for cells cultured with 4F-GlcNAc. Time course studies demonstrated reduced CLA/HECA and LacNAc (detected by DSA-lectin) expression on PSGL-1 in 4F-GalNAc treated cells beginning at 9-18h. No change was noted in GalNAc control (Fig. 5c-d) .
Immunoprecipitation of PSGL-1 followed by western blot analysis verified results from cytometry-bead assays. CLA/HECA antigen associated with PSGL-1 was reduced by 4F-GalNAc, but not GalNAc or 4F-GlcNAc (Fig. 5e) . Gels run for extended duration show that the apparent molecular weight For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 13 of PSGL-1 is reduced by 12.5% upon 4F-GalNAc addition (Fig. 5f ). After accounting for the molecular weight of the peptide backbone, this translates to a ~20% reduction in the total glycan content of PSGL-1.
Overall, the culture of cells with 4F-GalNAc results in a reduction in the LacNAc epitope, CLA/HECA expression and molecular weight of PSGL-1.
4F-GalNAc is metabolically incorporated into PSGL-1
HL-60 cells were cultured with per-acetylated [
14 C]4F-GalNAc for 38h under standard conditions, and the fate of the radioactive compound was followed. 2-3% of the radioactivity was associated with the cellular glycoproteins while a majority of the compound remained in the culture media (Table 1) . With regard to this observation, since HL-60 cells (0.7×10 6 cells/ml, ~15.6μm diameter) constitute only 0.14% of the volume of the experimental well (1ml), 3% of 4F-GalNAc associated with the cells represents a relatively high intra-cellular concentration of the modified monosaccharide
Since 97% of the total radioactivity was associated with the culture media ( cells. Media recovered at 38h were separated using a Biogel P-2 column (Fig. 6a, 6b Fig. 6b ). Eluates corresponding to these peaks were separated using thin layer chromatography/TLC (Fig. 6c) and their migration was compared to non-radiolabeled per-acetylated 4F-GalNAc and non-acetylated 4F-GalNAc (~10μg) under identical conditions. As seen, the first peak (position 2 and 5) that is common between both runs contains primarily per-acetylated, 4F-GalNAc (Fig. 6c, lanes 2 and 5) . Some product also appeared at intermediate distances between the per-acetylated and de-acetylated 4F-GalNAc and this likely represents 4F-GalNAc that was partially hydrolyzed in culture media. In this regard, the original
[
14 C]4F-GalNAc diluted and kept in DMSO under the same culture conditions appeared as a unique spot that migrated identically to fully-acetylated 4F-GalNAc shown in lane 7 (Fig. 6c) . The second peak (position 3, lane 3), that is unique to experiments containing HL-60, migrated identically to nonacetylated 4F-GalNAc. This may represent 4F-GalNAc that was de-acetylated inside cells prior to being secreted/diffusing out from the cells.
In another assay, radioactivity associated with PSGL-1 was determined by immunoprecipitating the protein using Ab H-300, separation on 4-20% gradient gel and transfer to nitrocellulose membrane.
Phosphorimaging of membrane was subsequently performed. Supernatant depleted of PSGL-1 was also analyzed in parallel. This study demonstrates the direct incorporation of 4F-GalNAc into leukocyte PSGL-1 and also other glycoproteins (Fig. 6d ). Radioactivity associated with leukocyte glycoproteins could be partially removed by α -N-acetylgalactosaminidase (Supplemental Fig. S4 ) and this confirms that the radioactivity measured is associated with O-glycans. Overall, 4F-GalNAc is metabolically active and it can be incorporated into multiple cellular glycoproteins including PSGL-1.
4F-GalNAc reduced leukocyte recruitment to inflamed peritoneum
We determined if 4F-GalNAc can reduce selectin mediated leukocyte recruitment at sites of inflammation (Figure 7) . Bone marrow cells (BMCs) from C57BL/6 mouse femur were cultured ex vivo with either vehicle control or per-acetylated monosaccharides. These BMCs consist predominantly of functional neutrophils [39] [40] [41] . Consistent with these reports we also observed, following 2 days of ex vivo culture in the presence of 20ng/ml G-CSF and 1ng/ml IL-3, that a majority of LDS-751 + nucleated cells were positive for both granulocytic markers Gr-1 and 1A8/Ly-6-G (Supplemental Fig. S5 ). These cells, which appear in region R1 in the flow cytometry dot plot (Fig. 7a) , expressed mouse PSGL-1 and CD45, and they bound human P-selectin fusion protein (Fig. 7b, and Supplemental Fig. S5 ). Cells in region R2
represent 28% of the LDS-751 + cells and these did not stain for granulocyte markers. Culture of BMCs with 25µM 4F-GalNAc, but not 25µM GalNAc or vehicle control, led to a 62% decrease in P-selectinIgG binding to granulocytes (Fig. 7b) . While CD45 expression was not altered under any of the growth
conditions, a 22% and 14% reduction in PSGL-1 was noted upon culture with per-acetylated 4F-GalNAc and GalNAc respectively. In control runs, P-selectin-IgG binding to mouse cells could be abrogated by 10μg/mL mouse anti-human P-selectin/CD62P blocking antibody G1, 3mM sLe X analog TBC1269 and 5mM EDTA.
We tested the hypothesis that 4F-GalNAc may reduce selectin mediated leukocyte adhesion in mice. Thus, BMCs cultured ex vivo for two days in the presence of 25µM 4F-GalNAc or vehicle-control were differentially labeled with lipophilic tracers, DiL (red fluorescence) or DiO (green fluorescence).
These cells were mixed in 1:1 proportion and introduced into recipient C57BL/6 mice via tail-vein injection. Peritonitis was immediately induced by intraperitoneal injection of thioglycollate 36 . In this model of inflammation, granulocytes constitute >70% of the cells in the peritoneal lavage 5h after induction of peritonitis 36 . Flow cytometry analysis of granulocytes (Gr-1 + ) just after labeling (Fig. 7c ) and from the peritoneal lavage (Fig. 7d, (Fig. 7f) . % reduction in cell migration was 60% when the labeling protocol was reversed, i.e. 4F-GalNAc treated cells were stained with DiO.
In other studies, 4F-GalNAc or vehicle control was tail-vein injected at 100mg/kg/day into mice for 4 days (Fig. 7g) . There was no evidence of toxicity, outward signs of distress, or alteration in the alertness/movement of the animals treated with 4F-GalNAc. Pharmacological activity of the monosaccharide analog was confirmed since there was a 40-50% reduction in total leukocyte, neutrophil, macrophage and eosinophil count in the peritoneum in 4F-GalNAc treated animals 5h after induction of peritonitis.
For
DISCUSSION
Experiments were performed to test the possibility that 4F-GalNAc may alter O-linked glycosylation and reduce selectin mediated cell adhesion. Consistent with this proposition, 4F-GalNAc addition to leukocytes reduced selectin fusion protein binding to HL-60 cells (Fig. 2, 3) , increased HL-60 rolling velocity under fluid shear conditions (Fig. 4) , reduced the CLA/HECA epitope expression on the glycoprotein PSGL-1 (Fig. 5) , and inhibited leukocyte migration in a murine model of inflammation (Fig.   7 ). In the last experiments, BMCs cultured ex vivo with 4F-GalNAc displayed reduced migration into the peritoneum during inflammation. Direct intravenous infusion of 4F-GalNAc also reduced leukocyte recruitment and thus the compound is pharmacologically active. shown that Core-2 forming enzyme β1,6GlcNAcT recognizes many of the -OH groups in the glycan core 1 (Galβ1,3GalNAc) structure. Hydroxyl groups at the C-4 and C-6 positions of both Gal and GalNAc along with the C-2 N-acetyl group are shown to be essential for full activity of this enzyme. Second, it may be possible that monosaccharide analogs may act as inhibitors of specific glycosyltransferases, like fucosyltransferases. In this regard, native 4F-GalNAc, its nucleotide form UDP-4F-GalNAc or specific glycoconjugates formed due to 4F-GalNAc incorporation may display enzyme inhibition function. Third, besides the initial steps that regulate 4F-GalNAc incorporation into glycoconjugates, later steps like the time course of 4F-GalNAc accumulation in cells and cellular recycling/salvage pathways may also be important at later times following the first cell division step. While each of the aspects above is not
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While 4F-GalNAc was well tolerated by cells in our study, we noted that the compound was also incorporated into other proteins besides PSGL-1. 4F-GalNAc, like 4F-GlcNAc, also altered the glycosaminoglycan content of cells (S.N., unpublished data). In this regard, 4F-GalNAc reduces chondroitin sulfate biosynthesis. Others have shown that 4F-GlcNAc reduces both heparan sulfate and chondroitin sulfate biosynthesis 50 . Thus, the pathways engaged are not specific to PSGL-1 alone, and the functional consequence of this remains to be studied. We also noted a 10-15% reduction in cell growth rate at 38h compared to the vehicle/untreated control. Such non-specific effects are common to many other studies that use metabolic approaches to target cell adhesion. For example, Sharma et al 22 demonstrate that both 4F-GalNAc and 4F-GlcNAc can reduce cell growth to a similar extent. Similar 10-15% reduction in cell growth is also reported in studies that employ decoys Galβ1,4GlcNAc-NM and GlcNAcβ1,3Gal-NM to reduce selectin binding 14 . While reduction in cell growth is noted in these studies, metabolic labeling studies that employ radioactive carbohydrate and amino acid precursors show that protein synthesis is only reduced at extracellular concentrations in the 0.3-1mM range 22 . Another study also notes that 100μM 4F-GalNAc and 4F-GlcNAc have no adverse effects on cellular protein biosynthesis 25 .
Overall, the manuscript introduces 4F-GalNAc as a potential modifier of O-linked glycosylation.
The in vitro and in vivo studies suggest that the compound can reduce the expression of the sialyl Lewis-X epitope on glycoproteins, and diminish selectin-mediated cell adhesion.
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